Activity of cetuximab as single agent in a patient with relapsed multiple myeloma

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 562-564

  Böll, Boris ^a,b   Eichenauer, Dennis A ^a   Von Tresckow, Bastian ^a,b   Peine, Denissa ^a   Hallek, Michael ^a   Engert, Andreas ^a   Hübel, Kai ^a  

^a Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CETUXIMAB; DEXAMETHASONE; DIMETINDENE; DOXORUBICIN; DOXYCYCLINE; ERYTHROMYCIN; MELPHALAN; RANITIDINE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G; LIGAND; MONOCLONAL ANTIBODY;

ACNE; ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RELAPSE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULIN G; LIGANDS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77249162670     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903580428     Document Type: Letter

References (10)

1. Harousseau JL, Moreau P. Autologous hematopoietic stemcell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-2654.
2. Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 2009;83:279-289.
3. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9: 278-288.
4. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009;23:449-456.
5. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1-9.
6. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-385. (Pubitemid 44142736)
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
8. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
9. Mahtouk K, Hose D, Reme T, et al. Expression of EGFfamily receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005;24:3512-3524.
10. Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti- IL-6 antibody-induced apoptosis. Blood 2004;103:1829-1837.